[go: up one dir, main page]

MXPA03011260A - Receptor acoplado a proteina g y usos del mismo. - Google Patents

Receptor acoplado a proteina g y usos del mismo.

Info

Publication number
MXPA03011260A
MXPA03011260A MXPA03011260A MXPA03011260A MXPA03011260A MX PA03011260 A MXPA03011260 A MX PA03011260A MX PA03011260 A MXPA03011260 A MX PA03011260A MX PA03011260 A MXPA03011260 A MX PA03011260A MX PA03011260 A MXPA03011260 A MX PA03011260A
Authority
MX
Mexico
Prior art keywords
hcar
protein
methods
hcar protein
gene
Prior art date
Application number
MXPA03011260A
Other languages
English (en)
Inventor
Gaither Bates Brian
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA03011260A publication Critical patent/MXPA03011260A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invencion se basa en la identificacion de un receptor acoplado a proteina G (GPCR) que es expresado predominantemente en el cerebro y en la placenta y moleculas de acido nucleico que codifican para el GPCR, las cuales son referidas aqui como la proteina hCAR y el gen de hCAR, respectivamente (para el Receptor Constitutivamente Activo Humano). Sobre la base de esta identificacion, la presente invencion proporciona: (1) proteina hCAR aislada; (2) moleculas de acido nucleico aisladas que codifican para una proteina hCAR; (3) anticuerpos que se unen selectivamente a la proteina hCAR; (4) metodos para aislar variantes alelicas de la proteina y el gen de hCAR; (5) metodos para identificar celulas y tejidos que expresan la proteina/gen de hCAR; (6) metodos para identificar agentes y compuestos celulares que se unen a la proteina hCAR; (7) metodos para identificar agentes que modulen la expresion del gen de hCAR; (8) metodos para modular la actividad de la proteina hCAR en una celula u organismo.
MXPA03011260A 2001-06-07 2002-05-30 Receptor acoplado a proteina g y usos del mismo. MXPA03011260A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29713101P 2001-06-07 2001-06-07
PCT/US2002/016834 WO2002101005A2 (en) 2001-06-07 2002-05-30 A g-protein coupled receptor and uses therefor

Publications (1)

Publication Number Publication Date
MXPA03011260A true MXPA03011260A (es) 2004-02-27

Family

ID=23144983

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011260A MXPA03011260A (es) 2001-06-07 2002-05-30 Receptor acoplado a proteina g y usos del mismo.

Country Status (10)

Country Link
US (3) US20030022211A1 (es)
EP (1) EP1392845A4 (es)
JP (1) JP2004537297A (es)
BR (1) BR0210283A (es)
CA (1) CA2449649A1 (es)
MX (1) MXPA03011260A (es)
NO (1) NO20035319D0 (es)
PL (1) PL370139A1 (es)
WO (1) WO2002101005A2 (es)
ZA (1) ZA200400074B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5112557B2 (ja) 2009-02-19 2013-01-09 株式会社日立ハイテクノロジーズ 質量分析システム
SG11202103334YA (en) 2018-10-26 2021-05-28 Hoffmann La Roche Multispecific antibody screening method using recombinase mediated cassette exchange
EP3947437A1 (en) 2019-03-29 2022-02-09 F. Hoffmann-La Roche AG Method for the generation of an fcrn expressing cell by targeted integration of multiple expression cassettes in a defined organization
WO2022094190A2 (en) 2020-10-30 2022-05-05 Milwaukee Electric Tool Corporation Powered fastener driver

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5272057A (en) * 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US5498531A (en) * 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5691188A (en) * 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
FR2755536B1 (fr) * 1996-11-07 1998-12-04 Schneider Electric Sa Declencheur electromagnetique reglable et disjoncteur comportant un tel declencheur
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
JP2003510027A (ja) * 1999-08-17 2003-03-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Ｐｇｐｃｒ−３ポリペプチドおよびそのｄｎａ配列
WO2001036473A2 (en) * 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Human g protein-coupled receptors
CN1310945C (zh) * 1999-11-17 2007-04-18 阿瑞那制药公司 人g蛋白偶联受体的内源形式和非内源形式
WO2002032962A2 (en) * 2000-10-20 2002-04-25 Millennium Pharmaceuticals, Inc. Compositions of human proteins and method of use thereof
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders

Also Published As

Publication number Publication date
PL370139A1 (en) 2005-05-16
CA2449649A1 (en) 2002-12-19
ZA200400074B (en) 2006-06-28
WO2002101005A3 (en) 2003-07-31
JP2004537297A (ja) 2004-12-16
BR0210283A (pt) 2004-09-14
US20070031860A1 (en) 2007-02-08
EP1392845A4 (en) 2005-10-05
US20090255004A1 (en) 2009-10-08
EP1392845A2 (en) 2004-03-03
WO2002101005A2 (en) 2002-12-19
NO20035319D0 (no) 2003-11-28
US20030022211A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
SI2105449T1 (sl) Antagonistična selektivna vezavna sredstva osteoprotegerin-vezavnega proteina
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
EP2284185A3 (en) Bacillus protein inactivation
WO2002031134A3 (en) Novel serine protease genes related to dppiv
WO1998031818A3 (en) Tace-like and matrilysin-like polypeptides
MXPA05007781A (es) Constructos de fusion y uso de los mismos para producir anticuerpos con afinidad incrementada de enlace al receptor fc y funcion efectora.
EP0701563A4 (en) GEN TRANSFER FOR TREATING CONSTRUCTIVE TISSUE OF A MAMMAL HOST
EP1517144A3 (en) Method of identifying an antibody binding to and modulating the activity of a human vanilloid receptor
ATE331791T1 (de) Phosphodiesterase 10
AU2002239229A1 (en) Receptor for b. anthracis toxin
MXPA03011260A (es) Receptor acoplado a proteina g y usos del mismo.
WO1998011234A3 (en) Human protein kinases
WO2003055908A3 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
WO2004054510A3 (en) Method for identifying modulators of human orexin-2 receptor
WO2003088910A3 (en) Methods of assaying for cell cycle modulators
WO2001042285A3 (en) Extracellular matrix and cell adhesion proteins as well as genes encoding them
ATE302214T1 (de) Enamel-matrix bezogene polypeptide
WO1999058641A8 (en) Nt2lp, novel g-protein coupled receptors having homology to neurotensin-2 receptors
WO2002059345A3 (en) Nucleic acid encoding ion transporter component protein
WO1994019463A3 (en) Developmental tyrosine kinases and their ligands
CA2404679A1 (en) Adenine binding g-protein coupled receptors
WO2003095622A3 (en) Proteins associated with cell growth, differentiation, and death
WO2000007545A3 (en) Apoptosis proteins
WO2003087332A3 (en) Novel polynucleotides encoding the human citron kinase polypeptide, bmsnkc 0020/0021